Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Pocock

Showing results (121-130 of 349) with videos related to

Pageof 35
Sort By:
Plos Medicine|October 19, 2007
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaborationJan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
Journal of the American College of Cardiology|March 19, 2021
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-ReducedJoão Pedro Ferreira, Faiez Zannad, Stuart J Pocock, et al.
The New England Journal of Medicine|August 27, 2021
Empagliflozin and Major Renal Outcomes in Heart FailureMilton Packer, Javed Butler, Faiez Zannad, et al.
Epidemiology (Cambridge, Mass.)|December 1, 2007
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaborationJan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
BMJ (Clinical Research Ed.)|October 8, 2004
Issues in the reporting of epidemiological studies: a survey of recent practiceStuart J Pocock, Timothy J Collier, Kimberley J Dandreo, et al.
Gaceta Sanitaria|March 3, 2009
[Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]Jan P Vandenbroucke, Erik Von Elm, Douglas G Altman, et al.
Annals of Internal Medicine|October 17, 2007
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaborationJan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
Lancet (London, England)|June 9, 2009
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Ewha Medical Journal|July 24, 2025
[Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration - a Korean translation]Jan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
Circulation|October 9, 2012
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizationsJennifer K Rogers, John J V McMurray, Stuart J Pocock, et al.
Pageof 35

Showing results (121-130 of 349) with videos related to

Sort By:
Pageof 35
Plos Medicine|October 19, 2007
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaborationJan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
Journal of the American College of Cardiology|March 19, 2021
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-ReducedJoão Pedro Ferreira, Faiez Zannad, Stuart J Pocock, et al.
The New England Journal of Medicine|August 27, 2021
Empagliflozin and Major Renal Outcomes in Heart FailureMilton Packer, Javed Butler, Faiez Zannad, et al.
Epidemiology (Cambridge, Mass.)|December 1, 2007
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaborationJan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
BMJ (Clinical Research Ed.)|October 8, 2004
Issues in the reporting of epidemiological studies: a survey of recent practiceStuart J Pocock, Timothy J Collier, Kimberley J Dandreo, et al.
Gaceta Sanitaria|March 3, 2009
[Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]Jan P Vandenbroucke, Erik Von Elm, Douglas G Altman, et al.
Annals of Internal Medicine|October 17, 2007
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaborationJan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
Lancet (London, England)|June 9, 2009
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Ewha Medical Journal|July 24, 2025
[Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration - a Korean translation]Jan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
Circulation|October 9, 2012
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizationsJennifer K Rogers, John J V McMurray, Stuart J Pocock, et al.
Pageof 35